235 related articles for article (PubMed ID: 8491220)
1. Somatostatin analogue scintigraphy in carcinoid tumours.
Kwekkeboom DJ; Krenning EP; Bakker WH; Oei HY; Kooij PP; Lamberts SW
Eur J Nucl Med; 1993 Apr; 20(4):283-92. PubMed ID: 8491220
[TBL] [Abstract][Full Text] [Related]
2. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
[TBL] [Abstract][Full Text] [Related]
3. Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue.
Dörr U; Räth U; Sautter-Bihl ML; Guzman G; Bach D; Adrian HJ; Bihl H
Eur J Nucl Med; 1993 May; 20(5):431-3. PubMed ID: 8100192
[TBL] [Abstract][Full Text] [Related]
4. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
[TBL] [Abstract][Full Text] [Related]
5. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
Eising EG; Farahati J; Bier D; Knust EJ; Reiners C
Nuklearmedizin; 1995 Feb; 34(1):1-7. PubMed ID: 7724358
[TBL] [Abstract][Full Text] [Related]
6. Localization of metastatic gastroenteropancreatic tumours by somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-octreotide.
Hammond PJ; Arka A; Peters AM; Bloom SR; Gilbey SG
Q J Med; 1994 Feb; 87(2):83-8. PubMed ID: 8153292
[TBL] [Abstract][Full Text] [Related]
7. Combined diagnostic imaging with 131I-metaiodobenzylguanidine and 111In-pentetreotide in carcinoid tumours.
Taal BG; Hoefnagel CA; Valdés Olmos RA; Boot H
Eur J Cancer; 1996 Oct; 32A(11):1924-32. PubMed ID: 8943676
[TBL] [Abstract][Full Text] [Related]
8. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging.
Shi W; Johnston CF; Buchanan KD; Ferguson WR; Laird JD; Crothers JG; McIlrath EM
QJM; 1998 Apr; 91(4):295-301. PubMed ID: 9666953
[TBL] [Abstract][Full Text] [Related]
9. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours.
Oberg K; Eriksson B
Best Pract Res Clin Endocrinol Metab; 2005 Jun; 19(2):265-76. PubMed ID: 15763700
[TBL] [Abstract][Full Text] [Related]
10. Value of somatostatin receptor scintigraphy for preoperative localization of carcinoids.
Kisker O; Weinel RJ; Geks J; Zacara F; Joseph K; Rothmund M
World J Surg; 1996 Feb; 20(2):162-7. PubMed ID: 8661812
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors.
Krausz Y; Bar-Ziv J; de Jong RB; Ish-Shalom S; Chisin R; Shibley N; Glaser B
Am J Gastroenterol; 1998 Jan; 93(1):66-70. PubMed ID: 9448177
[TBL] [Abstract][Full Text] [Related]
12. [Primary and follow-up studies of patients with carcinoid metastases using indium 111 octreotide--rational use of Sandostatin].
Lipp RW; Hammer HF; Passath A; Dobnig H; Ramschak-Schwarzer S; Stiegler C; Leb G; Krejs GJ
Acta Med Austriaca; 1993; 20(1-2):42-4. PubMed ID: 8475679
[TBL] [Abstract][Full Text] [Related]
13. L-3-[123I]Iodo-alpha-methyltyrosine scintigraphy in carcinoid tumors: correlation with biochemical activity and comparison with [111In-DTPA-D-Phe1]-octreotide imaging.
Jager PL; Meijer WG; Kema IP; Willemse PH; Piers DA; de Vries EG
J Nucl Med; 2000 Nov; 41(11):1793-800. PubMed ID: 11079485
[TBL] [Abstract][Full Text] [Related]
14. Successful and unsuccessful approaches to imaging carcinoids: comparison of a radiolabelled tryptophan hydroxylase inhibitor with a tracer of biogenic amine uptake and storage, and a somatostatin analogue.
Macfarlane D; Gonin J; Wieland D; Mangner T; Froelich J; Beierwaltes W; Shapiro B
Eur J Nucl Med; 1996 Feb; 23(2):131-40. PubMed ID: 8925846
[TBL] [Abstract][Full Text] [Related]
15. [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment.
Janson ET; Westlin JE; Eriksson B; Ahlström H; Nilsson S; Oberg K
Eur J Endocrinol; 1994 Dec; 131(6):577-81. PubMed ID: 7804439
[TBL] [Abstract][Full Text] [Related]
16. [Somatostatin receptor scintigraphy. A new imaging procedure for the specific demonstration of carcinoids of the small intestine].
Dörr U; Räth U; Schürmann G; Höring E; Bach D; Wurm K; Scholz M; Adrian HJ; Bihl H
Rofo; 1993 Jan; 158(1):67-73. PubMed ID: 8425079
[TBL] [Abstract][Full Text] [Related]
17. Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
Ur E; Bomanji J; Mather SJ; Britton KE; Wass JA; Grossman AB; Besser GM
Clin Endocrinol (Oxf); 1993 May; 38(5):501-6. PubMed ID: 8101146
[TBL] [Abstract][Full Text] [Related]
18. Comparison of somatostatin analogue and metaiodobenzylguanidine scintigraphy for the detection of carcinoid tumours.
Nocaudie-Calzada M; Huglo D; Carnaille B; Proye C; Marchandise X
Eur J Nucl Med; 1996 Nov; 23(11):1448-54. PubMed ID: 8854840
[TBL] [Abstract][Full Text] [Related]
19. SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors.
Schillaci O; Scopinaro F; Angeletti S; Tavolaro R; Danieli R; Annibale B; Gualdi G; Delle Fave G
J Nucl Med; 1996 Sep; 37(9):1452-6. PubMed ID: 8790191
[TBL] [Abstract][Full Text] [Related]
20. [111-indium DTPA octreotide scintigraphy in colorectal liver metastases].
Seifert JK; Görges R; Bockisch A; Junginger T
Langenbecks Arch Chir; 1997; 382(6):332-6. PubMed ID: 9498205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
